secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-037924
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q2 net loss widens to $128.6M; cuts 2023 spend by 15%, completes SEQUOIA-HCM enrollment
--------------------------------------------------------------------------------

- Net loss of $128.6M ($1.34 loss per share) vs $19.8M ($0.23 loss) in Q2 2022.
- Revenue fell to $0.9M from $89.0M, primarily due to no mavacamten royalty revenue in 2023.
- Cash, equivalents and investments $592.6M at June 30, 2023.
- Completed enrollment in SEQUOIA-HCM with 282 patients; topline results expected by end of 2023.
- Revised 2023 operating expense guidance to $390-410M; net cash utilization ~$310-320M, saving ~15%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023037924/0000950170-23-037924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023037924/cytk-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer